Analyst consensus rating
Prothena Analyst Rating: Buy
PRTA is rated Buy by 5 analysts with a $21.40 target. As of 2026-08-23.
Direct answer
Prothena's consensus rating is Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $21.40.
Forecast evidence checked August 23, 2026.
Get free Prothena email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $9.45
- Average price target
- $21.40
- High price target
- $36.00
- Low price target
- $8.00
- Low target gap
- -15.3%
- Target upside
- +126.5%
- High target gap
- +281%
- Target range width
- 296.3%
- Consensus rating
- Buy
- Analysts
- 5
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Prothena?
Prothena has a verified Buy consensus. The same dataset has an average price target of $21.40.
How far are Prothena's low and high targets from the recorded price?
The low target implies -15.3%, while the high target implies +281%.
How many analysts are included in Prothena's consensus?
The verified consensus includes 5 analysts.
How is Prothena's target upside or downside calculated?
The average target of $21.40 is divided by the recorded price of $9.45, then one is subtracted to produce +126.5%. This does not guarantee a future return.
When was Prothena's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.